BioSpace News Archive

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio ® (formerly known as Optune ® ) concurrent with radiation therapy and temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM).

Castle Biosciences, Inc. today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023.

Glaukos Corporation today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues.

ZYUS Life Sciences Corporation today announced that it has strengthened its leadership team with the appointment of Scott Livingstone to the role of Vice President of Clinical Research.

Focal Medical, Inc. today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product.

Levity Products, Inc., an innovative provider of catheter stabilizers, today announced a strategic partnership with Domrex Pharma, Inc., a North American leader in healthcare product distribution.

Emergent BioSolutions today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS).

Danaher Corporation and the Innovative Genomics Institute launched a collaborative center to develop gene-editing therapies for rare and other diseases, with a goal of creating a new model for future development of a wide range of genomic medicines.